Manual Contouring Based Volumetric Evaluation for Colorectal Cancer with Liver Limited Metastases: A Comparison with RECIST

Fang, Weijia; Lam, Ka-On; Ng, S C; Choi, Cheuk-Wai; Kwong, Dora Lai Wan; Zheng, Shusen; Lee, Victor

doi:10.7314/apjcp.2013.14.7.4151

Cited by 3 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our discordance rate of 15% was similar to previous studies [ 3 , 5 ]. Fang et al demonstrated that volumetric evaluation showed good agreement with RECIST (κ = 0.779) and the discordance rate was 13.3% (6/45) [ 3 ]. In our study, two patients with PR determined by RECIST were considered as SD by volumetric assessment.…”

Section: Discussionsupporting

confidence: 92%

“…In unresectable, metastatic colorectal carcinoma, the first-line palliative chemotherapy consists of combination chemotherapy with 5- fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX) and 5-FU/LV/irinotecan (FOLFIRI) [ 2 ]. Evaluation of the liver metastases after chemotherapy is important in order to guide subsequent treatment and to make possible more effective salvage treatment that prolongs the patient survival [ 3 ]. Currently, the revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1) are most widely used to assess the response to treatment for solid tumors, based on measurement of the longest diameter of the target lesions [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic response assessment using 3D ultrasound for hepatic metastasis from colorectal cancer: Application of a personalized, 3D-printed tumor model using CT images

Choi¹,

Park²,

Hur³

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Background & aimsTo evaluate accuracy and reliability of three-dimensional ultrasound (3D US) for response evaluation of hepatic metastasis from colorectal cancer (CRC) using a personalized 3D-printed tumor model.MethodsTwenty patients with liver metastasis from CRC who underwent baseline and after chemotherapy CT, were retrospectively included. Personalized 3D-printed tumor models using CT were fabricated. Two radiologists measured volume of each 3D printing model using 3D US. With CT as a reference, we compared difference between CT and US tumor volume. The response evaluation was based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria.Results3D US tumor volume showed no significant difference from CT volume (7.18 ± 5.44 mL, 8.31 ± 6.32 mL vs 7.42 ± 5.76 mL in CT, p>0.05). 3D US provided a high correlation coefficient with CT (r = 0.953, r = 0.97) as well as a high inter-observer intraclass correlation (0.978; 0.958–0.988). Regarding response, 3D US was in agreement with CT in 17 and 18 out of 20 patients for observer 1 and 2 with excellent agreement (κ = 0.961).Conclusions3D US tumor volume using a personalized 3D-printed model is an accurate and reliable method for the response evaluation in comparison with CT tumor volume.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Therapeutic response assessment using 3D ultrasound for hepatic metastasis from colorectal cancer: Application of a personalized, 3D-printed tumor model using CT images

Choi¹,

Park²,

Hur³

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…There is evidence that CT-based volumetric assessment of metastases (seeded region growing method, slice-based segmentation or threshold-based segmentation) is more accurate for assessment of disease progression than the Response Evaluation Criteria In Solid Tumors (RECIST) V.1.1 method of largest axial diameter. 24 It is acknowledged that although RECIST criteria provide an objective means of assessment of solid tumour response to treatment, there is a risk of interobserver bias. 25 Further, RECIST criteria may be insufficient to assess response to treatment in patients with colorectal liver metastases treated by biological agents such as bevacizumab.…”

Section: Methods and Analysismentioning

confidence: 99%

Colorectal cancer with Synchronous liver-limited Metastases: the protocol of an Inception Cohort study (CoSMIC)

et al. 2017

View full text Add to dashboard Cite

IntroductionColorectal cancer is the fourth most common cancer in the UK and an important cause of cancer-related death. In 20% of patients, there is metastasis to the liver or beyond at the time of diagnosis. The management of synchronous disease is complex. Conventional surgery removes the colorectal primary first, followed by chemotherapy, with resection of liver metastases as a final step. Advances in the availability and safety of liver surgery, anaesthesia and critical care have made two alternative options feasible. The first is synchronous resection of the primary and liver metastases. The second is resection of the metastatic disease as the first step, termed the reverse or liver-first approach. Currently, evidence is inadequate to inform the selection of care pathway for patients with colorectal cancer and synchronous liver-limited metastases. Specifically, optimal pathways are not defined and there is a dearth of prospectively recorded cohort-defining factors influencing treatment selection or outcome.Methods and analysisColorectal cancer with Synchronous liver-limited Metastases: an Inception Cohort (CoSMIC) is an inception cohort study of patients with a new diagnosis of colorectal cancer with synchronous liver-limited metastases. The sequence of treatment received, and factors influencing treatment decisions, will be evaluated against European Society of Medical Oncology guidelines. Clinical data will be collected, and quality of life, morbidity, mortality and long-term outcome compared for different treatment sequences adjusted for prognostic factors. Disease-free survival or progression will be measured at 1, 2 and 5 years. A nested qualitative study will ascertain patient experiences and clinician perspectives on delivery of care.Ethics and disseminationThe full study protocol was independently peer reviewed by Professor Kees de Jong (University of Maastricht, Holland). CoSMIC has ethical approval from the National Health Service Research Ethics Committee (14/NW/1397). Results will be disseminated to healthcare professionals and patient groups, and may be used to design a definitive trial addressing areas of equipoise in treatment pathways, as well as optimising current pathways to improve outcomes and experiences.Trial registration numberNCT02456285, pre-results.

show abstract

Impact of CAPOX or FOLFOX4 on Spleen size, Platelet Count and Liver Function when Partnered Cetuximab as First-line Treatment for KRAS Wild-type Metastatic Colorectal Cancer

Lee¹,

Fang²,

Lam³

et al. 2015

Cancer Res Front

View full text Add to dashboard Cite

Manual Contouring Based Volumetric Evaluation for Colorectal Cancer with Liver Limited Metastases: A Comparison with RECIST

Cited by 3 publications

References 31 publications

Therapeutic response assessment using 3D ultrasound for hepatic metastasis from colorectal cancer: Application of a personalized, 3D-printed tumor model using CT images

Therapeutic response assessment using 3D ultrasound for hepatic metastasis from colorectal cancer: Application of a personalized, 3D-printed tumor model using CT images

Colorectal cancer with Synchronous liver-limited Metastases: the protocol of an Inception Cohort study (CoSMIC)

Impact of CAPOX or FOLFOX4 on Spleen size, Platelet Count and Liver Function when Partnered Cetuximab as First-line Treatment for KRAS Wild-type Metastatic Colorectal Cancer

Contact Info

Product

Resources

About